These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Endocrine aspects of bromocriptine therapy in Parkinsonism.
    Author: Shaw KM, Lees AJ, Franks S, Daggett P, Thompson BD, Stern GM.
    Journal: J Neural Transm; 1978; 43(2):153-60. PubMed ID: 104006.
    Abstract:
    Plasma growth hormone (GH) concentrations in Parkinsonian patients following 3 months optimum therapy with bromocriptine showed no significant change from pretreatment values, whilst plasma prolactin concentrations were uniformly suppressed. Pretreatment GH and prolactin levels were unrelated to clinical disability, and no correlation between hormonal changes and therapeutic response was found. These results suggest the presence of different dopaminergic receptor mechanisms for GH and prolactin release as well as between the extrapyramidal and neuroendocrine systems.
    [Abstract] [Full Text] [Related] [New Search]